1-2 of 2
Chiara Cavalloni
Close
Sort by
Journal Articles

Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?

Clinical Trials & Observations
Alessandra Tedeschi, Anna Maria Frustaci, Francesca Romana Mauro, Annalisa Chiarenza, Marta Coscia, Stefania Ciolli, Gianluigi Reda, Luca Laurenti, Marzia Varettoni, Roberta Murru, Claudia Baratè, Paolo Sportoletti, Antonino Greco, Chiara Borella, Valentina Rossi, Marina Deodato, Annalisa Biagi, Giulia Zamprogna, Angelo Curto Pelle, Gianfranco Lapietra, Candida Vitale, Francesca Morelli, Ramona Cassin, Alberto Fresa, Chiara Cavalloni, Massimiliano Postorino, Claudia Ielo, Roberto Cairoli, Francesco Di Raimondo, Marco Montillo, Giovanni Del Poeta
Journal: Blood Advances
Blood Adv (2021) 5 (24): 5490–5500.
https://doi.org/10.1182/bloodadvances.2021004824
Published: 2021
Includes: Supplemental data
Journal Articles

Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients

Clinical Trials & Observations
Margherita Maffioli, Toni Giorgino, Barbara Mora, Alessandra Iurlo, Elena Elli, Maria Chiara Finazzi, Marianna Caramella, Elisa Rumi, Maria Cristina Carraro, Nicola Polverelli, Mariella D’Adda, Simona Malato, Marianna Rossi, Alfredo Molteni, Alessandro Vismara, Cinzia Sissa, Francesco Spina, Michela Anghilieri, Daniele Cattaneo, Rossella Renso, Marta Bellini, Maria Luisa Pioltelli, Chiara Cavalloni, Daniela Barraco, Raffaella Accetta, Lorenza Bertù, Matteo Giovanni Della Porta, Francesco Passamonti
Journal: Blood Advances
Blood Adv (2019) 3 (21): 3196–3200.
https://doi.org/10.1182/bloodadvances.2019000646
Published: 2019
Includes: Supplemental data